Bioinformatic Analysis of KIT Juxtamembrane Domain Mutations in Syrian GIST Patients: Jigsaw Puzzle Completed

Overview

Journal J Egypt Natl Canc Inst

Specialty Oncology

Date 2023 Aug 13

PMID 37574490

Authors

Nour Pharaon

Wafa Habbal

Fawza Monem

Affiliations

Soon will be listed here.

Abstract

Background: The huge number of detected somatic KIT mutations highlights the necessity of in silico analyses that are almost absent in the relevant medical literature. The aim of this study is to report the mutation spectrum analysis of exon 11 encoding the juxtamembrane (JM) domain of the KIT gene in a group of Syrian GIST patients.

Methods: Forty-eight formalin-fixed paraffin-embedded GIST tissue samples, collected between 2006 and 2016, were retrieved from the pathological archives and analyzed for KIT exon 11 mutations by DNA sequencing. Structural/functional impact of detected variants was predicted using several bioinformatic tools.

Results: Twenty-one different variants have been detected in intron 10, exon 11, and intron 11 of the KIT gene, eight of which were novel changes. Mutations in exon 11 of the KIT gene were detected in 28 of 48 (58.3%) GIST patients and predicted to be pathogenic and cancer promoting. Specifically, age above 60 was very significantly associated with the negative selection of deletion mutations (p = .007), a phenomenon that points to deletion severity.

Conclusions: Six bioinformatic tools have proved efficient in predicting the impact of detected KIT variations in view of published structural, experimental, and clinical findings.

Citing Articles

Differential diagnosis of gastrointestinal stromal tumors versus leiomyomas by special stains.

Zhang S, Qin P, Ji H BMC Gastroenterol. 2024; 24(1):418.

PMID: 39574038 PMC: 11580362. DOI: 10.1186/s12876-024-03511-5.

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.

Cao L, Tian W, Zhao Y, Song P, Zhao J, Wang C Glob Med Genet. 2024; 11(4):251-262.

PMID: 39176108 PMC: 11341198. DOI: 10.1055/s-0044-1789204.

References

Dudzisz-Sledz M, Klimczak A, Bylina E, Rutkowski P . Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients. Cancers (Basel). 2022; 14(12). PMC: 9221273. DOI: 10.3390/cancers14122831. View

Zheng S, Huang K, Tao D, Pan Y . Gene mutations and prognostic factors analysis in extragastrointestinal stromal tumor of a Chinese three-center study. J Gastrointest Surg. 2011; 15(4):675-81. DOI: 10.1007/s11605-010-1292-x. View

Lennartsson J, Ronnstrand L . Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012; 92(4):1619-49. DOI: 10.1152/physrev.00046.2011. View

Roskoski Jr R . Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. Biochem Biophys Res Commun. 2005; 338(3):1307-15. DOI: 10.1016/j.bbrc.2005.09.150. View

Mol C, Lim K, Sridhar V, Zou H, Chien E, Sang B . Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem. 2003; 278(34):31461-4. DOI: 10.1074/jbc.C300186200. View

Ma Y, Yu S, He X, Xu Y, Wu F, Xia Y . Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. Onco Targets Ther. 2014; 7:637-43. PMC: 4014364. DOI: 10.2147/OTT.S60458. View

Haller F, Lobke C, Ruschhaupt M, Schulten H, Schwager S, Gunawan B . Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions. J Pathol. 2008; 216(2):225-35. DOI: 10.1002/path.2402. View

Chen P, Zong L, Zhao W, Shi L . Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. World J Gastroenterol. 2010; 16(33):4227-32. PMC: 2932930. DOI: 10.3748/wjg.v16.i33.4227. View

Calibasi G, Baskin Y, Alyuruk H, Cavas L, Oztop I, Sagol O . Molecular analysis of the KIT gene in gastrointestinal stromal tumors with novel mutations. Appl Immunohistochem Mol Morphol. 2013; 22(1):37-45. DOI: 10.1097/PAI.0b013e318284a074. View

10.

Zerbino D, Achuthan P, Akanni W, Amode M, Barrell D, Bhai J . Ensembl 2018. Nucleic Acids Res. 2017; 46(D1):D754-D761. PMC: 5753206. DOI: 10.1093/nar/gkx1098. View

11.

Smigielski E, Sirotkin K, Ward M, Sherry S . dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 1999; 28(1):352-5. PMC: 102496. DOI: 10.1093/nar/28.1.352. View

12.

Kumar P, Henikoff S, Ng P . Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7):1073-81. DOI: 10.1038/nprot.2009.86. View

13.

Adzhubei I, Schmidt S, Peshkin L, Ramensky V, Gerasimova A, Bork P . A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248-9. PMC: 2855889. DOI: 10.1038/nmeth0410-248. View

14.

Shihab H, Gough J, Cooper D, Day I, Gaunt T . Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics. 2013; 29(12):1504-10. PMC: 3673218. DOI: 10.1093/bioinformatics/btt182. View

15.

Shihab H, Rogers M, Gough J, Mort M, Cooper D, Day I . An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics. 2015; 31(10):1536-43. PMC: 4426838. DOI: 10.1093/bioinformatics/btv009. View

16.

Faber K, Glatting K, Mueller P, Risch A, Hotz-Wagenblatt A . Genome-wide prediction of splice-modifying SNPs in human genes using a new analysis pipeline called AASsites. BMC Bioinformatics. 2011; 12 Suppl 4:S2. PMC: 3194194. DOI: 10.1186/1471-2105-12-S4-S2. View

17.

Schwarz J, Cooper D, Schuelke M, Seelow D . MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11(4):361-2. DOI: 10.1038/nmeth.2890. View

18.

Kang H, Ryu M, Kim K, Park Y, Choi J, Ryoo B . Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol. 2011; 51(4):528-36. DOI: 10.3109/0284186X.2011.636753. View

19.

Chen J, Gundara J, Haddad R, Schiavone V, Meldrum C, Samra J . Clinicopathological and molecular aspects of foregut gastrointestinal stromal tumours. ANZ J Surg. 2012; 84(1-2):52-8. DOI: 10.1111/ans.12011. View

20.

Reichardt P, Demetri G, Gelderblom H, Rutkowski P, Im S, Gupta S . Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016; 16:22. PMC: 4714485. DOI: 10.1186/s12885-016-2051-5. View